300529 Stock Overview

Engages in the research, development, production, and sales of blood purification products for hemadsorption industry in China and internationally. More details

300529 fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	6/6
Past Performance	5/6
Financial Health	5/6
Dividends	3/6

Rewards

Price-To-Earnings ratio (28.7x) is below the CN market (37x)

Earnings are forecast to grow 26.14% per year

Earnings grew by 82.9% over the past year

Trading at good value compared to peers and industry

Risk Analysis

Unstable dividend track record

My Notes

Capture your thoughts, links and company narrative

Jafron Biomedical Co.,Ltd. Competitors

Lepu Medical Technology (Beijing)

SZSE:300003

CN¥21.9b

Double Medical Technology

SZSE:002901

CN¥12.5b

Jiangsu Yuyue Medical Equipment & Supply

SZSE:002223

CN¥35.3b

MeHow Innovative

SZSE:301363

CN¥13.0b

Price History & Performance

Summary of share price highs, lows and changes for Jafron BiomedicalLtd
Historical stock prices
Current Share Price	CN¥29.86
52 Week High	CN¥39.24
52 Week Low	CN¥15.88
Beta	0.36
1 Month Change	-4.57%
3 Month Change	19.92%
1 Year Change	34.38%
3 Year Change	-41.82%
5 Year Change	-17.94%
Change since IPO	264.85%

Recent updates

Jafron BiomedicalLtd (SZSE:300529) Is Reinvesting At Lower Rates Of Return

Dec 10

Jafron BiomedicalLtd (SZSE:300529) Seems To Use Debt Rather Sparingly

Nov 22

Earnings Report: Jafron Biomedical Co.,Ltd. Missed Revenue Estimates By 8.1%

Oct 21

Further Upside For Jafron Biomedical Co.,Ltd. (SZSE:300529) Shares Could Introduce Price Risks After 34% Bounce

Oct 02

Estimating The Fair Value Of Jafron Biomedical Co.,Ltd. (SZSE:300529)

Sep 09

The Returns On Capital At Jafron BiomedicalLtd (SZSE:300529) Don't Inspire Confidence

Aug 25

Jafron BiomedicalLtd's (SZSE:300529) Dividend Will Be Reduced To CN¥0.40

May 28

A Look At The Intrinsic Value Of Jafron Biomedical Co.,Ltd. (SZSE:300529)

May 24

Why Investors Shouldn't Be Surprised By Jafron Biomedical Co.,Ltd.'s (SZSE:300529) 30% Share Price Surge

May 08

Jafron BiomedicalLtd's (SZSE:300529) Soft Earnings Don't Show The Whole Picture

May 02

Investors Could Be Concerned With Jafron BiomedicalLtd's (SZSE:300529) Returns On Capital

Apr 13

Does Jafron BiomedicalLtd (SZSE:300529) Have A Healthy Balance Sheet?

Mar 22

Jafron Biomedical Co.,Ltd.'s (SZSE:300529) P/E Is Still On The Mark Following 31% Share Price Bounce

Mar 04

Shareholder Returns

	300529	CN Medical Equipment	CN Market
7D	-1.3%	-3.3%	-2.6%
1Y	34.4%	-10.4%	9.7%

Return vs Industry: 300529 exceeded the CN Medical Equipment industry which returned -9% over the past year.

Return vs Market: 300529 exceeded the CN Market which returned 11.3% over the past year.

Price Volatility

Is 300529's price volatile compared to industry and market?
300529 volatility
300529 Average Weekly Movement	8.9%
Medical Equipment Industry Average Movement	8.5%
Market Average Movement	8.7%
10% most volatile stocks in CN Market	12.8%
10% least volatile stocks in CN Market	5.8%

Stable Share Price: 300529 has not had significant price volatility in the past 3 months compared to the CN market.

Volatility Over Time: 300529's weekly volatility (9%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1989	2,780	Fan Dong	www.jafroninternational.com

Jafron Biomedical Co.,Ltd. engages in the research, development, production, and sales of blood purification products for hemadsorption industry in China and internationally. The company offers solutions for ESRD diseases, acute poisoning, critical illness, hepatopathy, immunological disorders, kidney, and liver diseases; HA series hemoperfusion cartridge, BS bilirubin adsorption column and DNA immunoadsorption column, hemoperfusion machine, and blood purification machine; and other products, such as hemodialyzer, hemodialysis concentrate, disinfectants, resin bandages, online hemodialysis powder bag/bucket, and adsorbable suture with needles.

Jafron Biomedical Co.,Ltd. Fundamentals Summary

How do Jafron BiomedicalLtd's earnings and revenue compare to its market cap?
300529 fundamental statistics
Market cap	CN¥23.12b
Earnings (TTM)	CN¥804.47m
Revenue (TTM)	CN¥2.63b

28.7x

P/E Ratio

8.8x

P/S Ratio

Is 300529 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
300529 income statement (TTM)
Revenue	CN¥2.63b
Cost of Revenue	CN¥508.40m
Gross Profit	CN¥2.12b
Other Expenses	CN¥1.32b
Earnings	CN¥804.47m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	1.04
Gross Margin	80.68%
Net Profit Margin	30.56%
Debt/Equity Ratio	49.1%

How did 300529 perform over the long term?

See historical performance and comparison

Dividends

1.3%

Current Dividend Yield

39%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/17 00:34
End of Day Share Price	2024/12/17 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Jafron Biomedical Co.,Ltd. is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Sophia Zhang	China Stock Investment Research Co. Ltd. (GZ500..com)
Shuo Song	Citic Securities Co., Ltd.
Xiao Wei Lin	Everbright Securities Co. Ltd.

300529 Stock Overview

Rewards

Risk Analysis

Jafron Biomedical Co.,Ltd. Competitors

SZSE:300003

CN¥21.9b

SZSE:002901

CN¥12.5b

SZSE:002223

CN¥35.3b

SZSE:301363

CN¥13.0b

Price History & Performance

Recent News & Updates

Jafron BiomedicalLtd (SZSE:300529) Is Reinvesting At Lower Rates Of Return

Jafron BiomedicalLtd (SZSE:300529) Seems To Use Debt Rather Sparingly

Now 27% overvalued after recent price rise

Consensus EPS estimates increase by 34%

Earnings Report: Jafron Biomedical Co.,Ltd. Missed Revenue Estimates By 8.1%

Now 22% overvalued after recent price rise

Recent updates

Jafron BiomedicalLtd (SZSE:300529) Is Reinvesting At Lower Rates Of Return

Jafron BiomedicalLtd (SZSE:300529) Seems To Use Debt Rather Sparingly

Now 27% overvalued after recent price rise

Consensus EPS estimates increase by 34%

Earnings Report: Jafron Biomedical Co.,Ltd. Missed Revenue Estimates By 8.1%

Now 22% overvalued after recent price rise

Third quarter 2024 earnings released: EPS: CN¥0.30 (vs CN¥0.18 in 3Q 2023)

Investor sentiment deteriorates as stock falls 20%

Further Upside For Jafron Biomedical Co.,Ltd. (SZSE:300529) Shares Could Introduce Price Risks After 34% Bounce

New minor risk - Share price stability

Jafron Biomedical Co.,Ltd. to Report Q3, 2024 Results on Oct 19, 2024

Now 20% overvalued after recent price rise

Investor sentiment improves as stock rises 17%

Estimating The Fair Value Of Jafron Biomedical Co.,Ltd. (SZSE:300529)

The Returns On Capital At Jafron BiomedicalLtd (SZSE:300529) Don't Inspire Confidence

Second quarter 2024 earnings released: EPS: CN¥0.34 (vs CN¥0.10 in 2Q 2023)

Jafron Biomedical Co.,Ltd. to Report First Half, 2024 Results on Aug 08, 2024

Jafron BiomedicalLtd's (SZSE:300529) Dividend Will Be Reduced To CN¥0.40

Dividend reduced to CN¥0.40

A Look At The Intrinsic Value Of Jafron Biomedical Co.,Ltd. (SZSE:300529)

Why Investors Shouldn't Be Surprised By Jafron Biomedical Co.,Ltd.'s (SZSE:300529) 30% Share Price Surge

Now 20% overvalued after recent price rise

Jafron BiomedicalLtd's (SZSE:300529) Soft Earnings Don't Show The Whole Picture

Jafron Biomedical Co.,Ltd., Annual General Meeting, May 20, 2024

Jafron Biomedical Co.,Ltd. Proposes Final Dividend for the Year 2023

First quarter 2024 earnings released: EPS: CN¥0.35 (vs CN¥0.25 in 1Q 2023)

Investors Could Be Concerned With Jafron BiomedicalLtd's (SZSE:300529) Returns On Capital

Jafron Biomedical Co.,Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Does Jafron BiomedicalLtd (SZSE:300529) Have A Healthy Balance Sheet?

Investor sentiment improves as stock rises 15%

Jafron Biomedical Co.,Ltd.'s (SZSE:300529) P/E Is Still On The Mark Following 31% Share Price Bounce

Investor sentiment improves as stock rises 16%

Jafron Biomedical Co.,Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024

New minor risk - Earnings quality

Third quarter 2023 earnings released: EPS: CN¥0.18 (vs CN¥0.16 in 3Q 2022)

Consensus revenue estimates fall by 13%

Investor sentiment improves as stock rises 16%

Jafron Biomedical Co.,Ltd. to Report Q3, 2023 Results on Oct 30, 2023

New minor risk - Profit margin trend

Second quarter 2023 earnings released: EPS: CN¥0.10 (vs CN¥0.51 in 2Q 2022)

Jafron Biomedical Co.,Ltd. to Report First Half, 2023 Results on Aug 23, 2023

Jafron Biomedical Co.,Ltd. Announces Cash Dividend on A Shares for the Year 2022, Payable on 31 May 2023

High number of new directors

Full year 2022 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

Investor sentiment deteriorated over the past week

Third quarter 2022 earnings released: EPS: CN¥0.16 (vs CN¥0.30 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.51 (vs CN¥0.43 in 2Q 2021)

Jafron Biomedical Co.,Ltd. Implements Final Cash Dividend (A Shares) for 2021, Payable on 10 June 2022

Jafron Biomedical Co.,Ltd. Approves Profit Distribution

Price target decreased to CN¥56.67

High number of new and inexperienced directors

Jafron Biomedical Co.,Ltd. Announces the Profit Distribution Proposal for 2021

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment deteriorated over the past week

Price target decreased to CN¥73.99

Third quarter 2021 earnings released: EPS CN¥0.30 (vs CN¥0.23 in 3Q 2020)

Jafron Biomedical Co.,Ltd. (SZSE:300529) commences an Equity Buyback Plan for CNY 500 million worth of its shares, under the authorization approved on September 14, 2021.